Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 80Neoplasm Metastasis 6Neoplasms 3Breast Neoplasms, Male 3Arthralgia 2Triple Negative Breast Neoplasms 1Sleep Wake Disorders 1Skin Diseases 1Prostatic Neoplasms 1Post Menopausal Women With Early Breast Cancer 1Pancreatic Neoplasms 1Pain 1Ovarian Neoplasms 1Obesity 1Metastatic Beast Cancer 1Mammary Neoplasms, Animal 1Lymphoma 1Lethal Congenital Contracture Syndrome 2 1Invasive Early Breast Cancer 1Human Epidermal Growth Factor 2 Negative Carcinoma of Breast 1Fatigue 1Estrogen-receptor Positive Invasive Metastatic Breast Cancer 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Diseases 1Breast Carcinoma In Situ 1Breast Cancer Metastatic 1Advanced Breast Carcinoma 1

Interventions

seribantumab 2zenocutuzumab 1exemestane 1Vinorelbine 1Trastuzumab 1Letrozole 1Fulvestrant 1Erlotinib Hydrochloride 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lethal Congenital Contracture Syndrome 2 × exemestane × Clear all
NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Merus B.V.

Phase 2 Completed
105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡